Scientists excel as CEOs because they are expert problem-solvers, experienced fundraisers (grant writing is like pitching VCs), and compelling storytellers (teaching complex topics is like pitching investors). These core academic skills are directly transferable to executive leadership but are often overlooked.
Instead of designing synthetic small molecules to block cancer-driving CDK kinases, which often cause toxic side effects, Concarlo uses a 'molecular glue' to lock the naturally selective p27 protein in its inhibitory state. This novel approach lets 'nature be selective for us,' increasing specificity and reducing toxicity.
Nearly 100% of patients on first-generation CDK4/6 inhibitors develop resistance. This occurs because CDK2, a related 'sibling' kinase, eventually compensates for the inhibited kinases and takes over their function. This predictable mechanism highlights the need for therapies that can safely inhibit all three kinases simultaneously.
Concarlo's technology was designed for p27, an intrinsically disordered protein (IDP) lacking a fixed structure. This same 'molecular glue' approach can be applied to other high-value but historically 'undruggable' IDP cancer targets, like p53 and MYC, creating a powerful drug discovery platform beyond their lead asset.
Faced with a male-dominated culture and stark funding gaps—only 2% of VC funding goes to women-led companies—female CEOs are building parallel support systems. Groups like the Biotech CEO Sisterhood provide mentorship and resource sharing, allowing members to bypass traditional, exclusionary networks and support one another.
Stacy Blain describes the 'if/when' trap: believing that "if I win the grant" or "when I get the promotion," you will finally be accepted into the establishment 'club'. She argues this is a fallacy, as external validation alone rarely overcomes systemic bias. The solution is to proactively build your own supportive networks instead.